{"pmid":32460173,"pmcid":"PMC7236671","title":"Clinical evaluation of AusDiagnostics SARS-CoV-2 multiplex tandem PCR assay.","text":["Clinical evaluation of AusDiagnostics SARS-CoV-2 multiplex tandem PCR assay.","BACKGROUND: In the context of the pandemic, the rapid emergency use authorisation of diagnostic assays for SARS-CoV-2 has meant there are few peer-reviewed published studies of clinical performance of commercial assays. AIMS: To evaluate the clinical performance of AusDiagnostics respiratory multiplex tandem PCR assay including SARS-CoV-2. METHODS: We reviewed the results following implementation of AusDiagnostics respiratory multiplex tandem PCR assay including SARS-CoV-2, and compared with an in-house RT-PCR assay at our State Reference Laboratory. RESULTS: Initial validation using AusDiagnostics coronavirus multiplex tandem PCR assay including SARS-CoV-2 demonstrated good concordance with the State Reference Laboratory. After implementing the AusDiagnostics respiratory multiplex tandem PCR assay including SARS-CoV-2, we tested 7839 samples. 127 samples in which SARS-CoV-2 was detected using the AusDiagnostics assay were referred for testing at the State Reference Laboratory, with concordant results in 118/127 (92.9%) of samples. After resolution of discrepancies, 125/127 (98.4%) of AusDiagnostics results were determined to be true positive results. Out of 7839 samples tested for SARS-CoV-2 during this period, only 2 tests (0.02%) were indeterminate results. CONCLUSION: The AusDiagnostics respiratory MT-PCR assay is a reliable assay for detection of SARS-CoV-2.","J Clin Virol","Attwood, Lucy O","Francis, Michelle J","Hamblin, John","Korman, Tony M","Druce, Julian","Graham, Maryza","32460173"],"abstract":["BACKGROUND: In the context of the pandemic, the rapid emergency use authorisation of diagnostic assays for SARS-CoV-2 has meant there are few peer-reviewed published studies of clinical performance of commercial assays. AIMS: To evaluate the clinical performance of AusDiagnostics respiratory multiplex tandem PCR assay including SARS-CoV-2. METHODS: We reviewed the results following implementation of AusDiagnostics respiratory multiplex tandem PCR assay including SARS-CoV-2, and compared with an in-house RT-PCR assay at our State Reference Laboratory. RESULTS: Initial validation using AusDiagnostics coronavirus multiplex tandem PCR assay including SARS-CoV-2 demonstrated good concordance with the State Reference Laboratory. After implementing the AusDiagnostics respiratory multiplex tandem PCR assay including SARS-CoV-2, we tested 7839 samples. 127 samples in which SARS-CoV-2 was detected using the AusDiagnostics assay were referred for testing at the State Reference Laboratory, with concordant results in 118/127 (92.9%) of samples. After resolution of discrepancies, 125/127 (98.4%) of AusDiagnostics results were determined to be true positive results. Out of 7839 samples tested for SARS-CoV-2 during this period, only 2 tests (0.02%) were indeterminate results. CONCLUSION: The AusDiagnostics respiratory MT-PCR assay is a reliable assay for detection of SARS-CoV-2."],"journal":"J Clin Virol","authors":["Attwood, Lucy O","Francis, Michelle J","Hamblin, John","Korman, Tony M","Druce, Julian","Graham, Maryza"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32460173","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.jcv.2020.104448","keywords":["covid-19","coronavirus","diagnosis","mt-pcr","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1668141322671751168,"score":9.490897,"similar":[{"pmid":32361322,"title":"Interpret with caution: An evaluation of the commercial AusDiagnostics versus in-house developed assays for the detection of SARS-CoV-2 virus.","text":["Interpret with caution: An evaluation of the commercial AusDiagnostics versus in-house developed assays for the detection of SARS-CoV-2 virus.","INTRODUCTION: There is limited data on the analytical performance of commercial nucleic acid tests (NATs) for laboratory confirmation of COVID-19 infection. METHODS: Nasopharyngeal, combined nose and throat swabs, nasopharyngeal aspirates and sputum was collected from persons with suspected SARS-CoV-2 infection, serial dilutions of SARS-CoV-2 viral cultures and synthetic positive controls (gBlocks, Integrated DNA Technologies) were tested using i) AusDiagnostics assay (AusDiagnostics Pty Ltd); ii) in-house developed assays targeting the E and RdRp genes; iii) multiplex PCR assay targeting endemic respiratory viruses. Discrepant SARS-CoV-2 results were resolved by testing the N, ORF1b, ORF1ab and M genes. RESULTS: Of 52 clinical samples collected from 50 persons tested, respiratory viruses were detected in 22 samples (42 %), including SARS CoV-2 (n=5), rhinovirus (n=7), enterovirus (n=5), influenza B (n=4), hMPV (n=5), influenza A (n=2), PIV-2 (n=1), RSV (n=2), CoV-NL63 (n=1) and CoV-229E (n=1). SARS-CoV-2 was detected in four additional samples by the AusDiagnostics assay. Using the in-house assays as the \"gold standard\", the sensitivity, specificity, positive and negative predictive values of the AusDiagnostics assay was 100 %, 92.16 %, 55.56 % and 100 % respectively. The Ct values of the real-time in-house-developed PCR assay targeting the E gene was significantly lower than the corresponding RdRp gene assay when applied to clinical samples, viral culture and positive controls (mean 21.75 vs 28.1, p=0.0031). CONCLUSIONS: The AusDiagnostics assay is not specific for the detection SARS-CoV-2. Any positive results should be confirmed using another NAT or sequencing. The case definition used to investigate persons with suspected COVID-19 infection is not specific.","J Clin Virol","Rahman, H","Carter, I","Basile, K","Donovan, L","Kumar, S","Tran, T","Ko, D","Alderson, S","Sivaruban, T","Eden, J-S","Rockett, R","O'Sullivan, M V","Sintchenko, V","Chen, S C-A","Maddocks, S","Dwyer, D E","Kok, J","32361322"],"abstract":["INTRODUCTION: There is limited data on the analytical performance of commercial nucleic acid tests (NATs) for laboratory confirmation of COVID-19 infection. METHODS: Nasopharyngeal, combined nose and throat swabs, nasopharyngeal aspirates and sputum was collected from persons with suspected SARS-CoV-2 infection, serial dilutions of SARS-CoV-2 viral cultures and synthetic positive controls (gBlocks, Integrated DNA Technologies) were tested using i) AusDiagnostics assay (AusDiagnostics Pty Ltd); ii) in-house developed assays targeting the E and RdRp genes; iii) multiplex PCR assay targeting endemic respiratory viruses. Discrepant SARS-CoV-2 results were resolved by testing the N, ORF1b, ORF1ab and M genes. RESULTS: Of 52 clinical samples collected from 50 persons tested, respiratory viruses were detected in 22 samples (42 %), including SARS CoV-2 (n=5), rhinovirus (n=7), enterovirus (n=5), influenza B (n=4), hMPV (n=5), influenza A (n=2), PIV-2 (n=1), RSV (n=2), CoV-NL63 (n=1) and CoV-229E (n=1). SARS-CoV-2 was detected in four additional samples by the AusDiagnostics assay. Using the in-house assays as the \"gold standard\", the sensitivity, specificity, positive and negative predictive values of the AusDiagnostics assay was 100 %, 92.16 %, 55.56 % and 100 % respectively. The Ct values of the real-time in-house-developed PCR assay targeting the E gene was significantly lower than the corresponding RdRp gene assay when applied to clinical samples, viral culture and positive controls (mean 21.75 vs 28.1, p=0.0031). CONCLUSIONS: The AusDiagnostics assay is not specific for the detection SARS-CoV-2. Any positive results should be confirmed using another NAT or sequencing. The case definition used to investigate persons with suspected COVID-19 infection is not specific."],"journal":"J Clin Virol","authors":["Rahman, H","Carter, I","Basile, K","Donovan, L","Kumar, S","Tran, T","Ko, D","Alderson, S","Sivaruban, T","Eden, J-S","Rockett, R","O'Sullivan, M V","Sintchenko, V","Chen, S C-A","Maddocks, S","Dwyer, D E","Kok, J"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361322","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.jcv.2020.104374","keywords":["covid-19","nat","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495895207936,"score":735.0668},{"pmid":32341142,"title":"Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the first rapid multiplex PCR commercial assay for SARS-CoV-2 detection.","text":["Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the first rapid multiplex PCR commercial assay for SARS-CoV-2 detection.","In the race to contain SARS-CoV-2, efficient detection and triage of infected patients must rely on rapid and reliable testing. In this work we performed the first evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel (QIAstat-SARS) for SARS-CoV-2 detection. This assay is the first rapid multiplex PCR (mPCR) assay including SARS-CoV-2 detection, and is fully compatible with a non-PCR trained laboratory or point-of-care (POC) testing.This evaluation was performed using 69 primary clinical samples (66 NPS, 1 BAL and 1 tracheal aspirate and 1 bronchial aspirate) comparing the SARS-CoV-2 detection with the currently WHO recommended RT-PCR (WHO-PCR) workflow. Additionally, a comparative limit of detection (LoD) assessment was performed between QIAstat-SARS and the WHO-PCR using a quantified clinical sample. Compatibility of sample pre-treatment for viral neutralisation or viscous samples with the QIAstat-SARS system were also tested.The QIAstat-Dx Respiratory SARS-CoV-2 Panel demonstrated a comparable sensitivity to the WHO recommended assay with a limit of detection at 1000 copies/mL. The overall percent agreement between QIAstat-Dx SARS and WHO-PCR on 69 clinical samples was 97% with a sensitivity at 100% (40/40) and specificity at 93% (27/29). No cross reaction was encountered for any other respiratory viruses or bacteria included in the panel.The QIAstat-SARS rapid multiplex-PCR panel provides a highly sensitive, robust and accurate assay for rapid detection of SARS-CoV-2. This assay allows rapid decisions even in non-PCR trained laboratory or point-of-care testing, allowing innovative organisation.","J Clin Microbiol","Visseaux, Benoit","Le Hingrat, Quentin","Collin, Gilles","Bouzid, Donia","Lebourgeois, Samuel","Le Pluart, Diane","Deconinck, Laurene","Lescure, Francois-Xavier","Lucet, Jean-Christophe","Bouadma, Lila","Timsit, Jean-Francois","Descamps, Diane","Yazdanpanah, Yazdan","Casalino, Enrique","Houhou-Fidouh, Nadhira","32341142"],"abstract":["In the race to contain SARS-CoV-2, efficient detection and triage of infected patients must rely on rapid and reliable testing. In this work we performed the first evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel (QIAstat-SARS) for SARS-CoV-2 detection. This assay is the first rapid multiplex PCR (mPCR) assay including SARS-CoV-2 detection, and is fully compatible with a non-PCR trained laboratory or point-of-care (POC) testing.This evaluation was performed using 69 primary clinical samples (66 NPS, 1 BAL and 1 tracheal aspirate and 1 bronchial aspirate) comparing the SARS-CoV-2 detection with the currently WHO recommended RT-PCR (WHO-PCR) workflow. Additionally, a comparative limit of detection (LoD) assessment was performed between QIAstat-SARS and the WHO-PCR using a quantified clinical sample. Compatibility of sample pre-treatment for viral neutralisation or viscous samples with the QIAstat-SARS system were also tested.The QIAstat-Dx Respiratory SARS-CoV-2 Panel demonstrated a comparable sensitivity to the WHO recommended assay with a limit of detection at 1000 copies/mL. The overall percent agreement between QIAstat-Dx SARS and WHO-PCR on 69 clinical samples was 97% with a sensitivity at 100% (40/40) and specificity at 93% (27/29). No cross reaction was encountered for any other respiratory viruses or bacteria included in the panel.The QIAstat-SARS rapid multiplex-PCR panel provides a highly sensitive, robust and accurate assay for rapid detection of SARS-CoV-2. This assay allows rapid decisions even in non-PCR trained laboratory or point-of-care testing, allowing innovative organisation."],"journal":"J Clin Microbiol","authors":["Visseaux, Benoit","Le Hingrat, Quentin","Collin, Gilles","Bouzid, Donia","Lebourgeois, Samuel","Le Pluart, Diane","Deconinck, Laurene","Lescure, Francois-Xavier","Lucet, Jean-Christophe","Bouadma, Lila","Timsit, Jean-Francois","Descamps, Diane","Yazdanpanah, Yazdan","Casalino, Enrique","Houhou-Fidouh, Nadhira"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32341142","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1128/JCM.00630-20","topics":["Diagnosis"],"weight":1,"_version_":1666138495106678785,"score":472.6412},{"pmid":32388471,"title":"Clinical evaluation of a SARS-CoV-2 RT-PCR assay on a fully automated system for rapid on-demand testing in the hospital setting.","text":["Clinical evaluation of a SARS-CoV-2 RT-PCR assay on a fully automated system for rapid on-demand testing in the hospital setting.","BACKGROUND: The ongoing SARS-CoV-2 pandemic presents a unique challenge for diagnostic laboratories around the world. Automation of workflows in molecular diagnostics is instrumental for coping with the large number of tests ordered by clinicians, as well as providing fast-tracked rapid testing for highly urgent cases. In this study we evaluated a SARS-CoV-2 LDT for the NeuMoDx 96 system, a fully automated device performing extraction and real-time PCR. METHODS: A publicly available SARS-CoV-2 RT-PCR assay was adapted for the automated system. Analytical performance was evaluated using in-vitro transcribed RNA and clinical performance was compared to the cobas 6800-based reference assay within the lab. RESULTS: The Envelope (E) Gene-LDT displayed good analytical performance with an LoD of 95.55 cp/mL and no false positives during evaluation of cross-reactivity. A total of 176 patient samples were tested with both the E-Gene-LDT and the reference assay. Positive and negative agreement were 100 % and 99.2 % respectively. Invalid-rate was 6.3 %. CONCLUSION: The E-Gene-LDT showed analytical and clinical performance comparable to the cobas6800-based reference assay. Due to its random-access workflow concept and rapid time-to-result of about 80 min, the system is very well suited for providing fast-tracked SARS-CoV-2 diagnostics for urgent clinical samples in the hospital setting.","J Clin Virol","Norz, Dominik","Fischer, Nicole","Schultze, Alexander","Kluge, Stefan","Mayer-Runge, Ulrich","Aepfelbacher, Martin","Pfefferle, Susanne","Lutgehetmann, Marc","32388471"],"abstract":["BACKGROUND: The ongoing SARS-CoV-2 pandemic presents a unique challenge for diagnostic laboratories around the world. Automation of workflows in molecular diagnostics is instrumental for coping with the large number of tests ordered by clinicians, as well as providing fast-tracked rapid testing for highly urgent cases. In this study we evaluated a SARS-CoV-2 LDT for the NeuMoDx 96 system, a fully automated device performing extraction and real-time PCR. METHODS: A publicly available SARS-CoV-2 RT-PCR assay was adapted for the automated system. Analytical performance was evaluated using in-vitro transcribed RNA and clinical performance was compared to the cobas 6800-based reference assay within the lab. RESULTS: The Envelope (E) Gene-LDT displayed good analytical performance with an LoD of 95.55 cp/mL and no false positives during evaluation of cross-reactivity. A total of 176 patient samples were tested with both the E-Gene-LDT and the reference assay. Positive and negative agreement were 100 % and 99.2 % respectively. Invalid-rate was 6.3 %. CONCLUSION: The E-Gene-LDT showed analytical and clinical performance comparable to the cobas6800-based reference assay. Due to its random-access workflow concept and rapid time-to-result of about 80 min, the system is very well suited for providing fast-tracked SARS-CoV-2 diagnostics for urgent clinical samples in the hospital setting."],"journal":"J Clin Virol","authors":["Norz, Dominik","Fischer, Nicole","Schultze, Alexander","Kluge, Stefan","Mayer-Runge, Ulrich","Aepfelbacher, Martin","Pfefferle, Susanne","Lutgehetmann, Marc"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388471","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104390","keywords":["covid-19","neumodx","pcr","rapid testing","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1666428892759457792,"score":371.5799},{"pmid":32276333,"pmcid":"PMC7177594","title":"Development of a Novel, Genome Subtraction-Derived, SARS-CoV-2-Specific COVID-19-nsp2 Real-Time RT-PCR Assay and Its Evaluation Using Clinical Specimens.","text":["Development of a Novel, Genome Subtraction-Derived, SARS-CoV-2-Specific COVID-19-nsp2 Real-Time RT-PCR Assay and Its Evaluation Using Clinical Specimens.","The pandemic novel coronavirus infection, Coronavirus Disease 2019 (COVID-19), has affected at least 190 countries or territories, with 465,915 confirmed cases and 21,031 deaths. In a containment-based strategy, rapid, sensitive and specific testing is important in epidemiological control and clinical management. Using 96 SARS-CoV-2 and 104 non-SARS-CoV-2 coronavirus genomes and our in-house program, GolayMetaMiner, four specific regions longer than 50 nucleotides in the SARS-CoV-2 genome were identified. Primers were designed to target the longest and previously untargeted nsp2 region and optimized as a probe-free real-time reverse transcription-polymerase chain reaction (RT-PCR) assay. The new COVID-19-nsp2 assay had a limit of detection (LOD) of 1.8 TCID50/mL and did not amplify other human-pathogenic coronaviruses and respiratory viruses. Assay reproducibility in terms of cycle threshold (Cp) values was satisfactory, with the total imprecision (% CV) values well below 5%. Evaluation of the new assay using 59 clinical specimens from 14 confirmed cases showed 100% concordance with our previously developed COVID-19-RdRp/Hel reference assay. A rapid, sensitive, SARS-CoV-2-specific real-time RT-PCR assay, COVID-19-nsp2, was developed.","Int J Mol Sci","Yip, Cyril Chik-Yan","Ho, Chi-Chun","Chan, Jasper Fuk-Woo","To, Kelvin Kai-Wang","Chan, Helen Shuk-Ying","Wong, Sally Cheuk-Ying","Leung, Kit-Hang","Fung, Agnes Yim-Fong","Ng, Anthony Chin-Ki","Zou, Zijiao","Tam, Anthony Raymond","Chung, Tom Wai-Hin","Chan, Kwok-Hung","Hung, Ivan Fan-Ngai","Cheng, Vincent Chi-Chung","Tsang, Owen Tak-Yin","Tsui, Stephen Kwok Wing","Yuen, Kwok-Yung","32276333"],"abstract":["The pandemic novel coronavirus infection, Coronavirus Disease 2019 (COVID-19), has affected at least 190 countries or territories, with 465,915 confirmed cases and 21,031 deaths. In a containment-based strategy, rapid, sensitive and specific testing is important in epidemiological control and clinical management. Using 96 SARS-CoV-2 and 104 non-SARS-CoV-2 coronavirus genomes and our in-house program, GolayMetaMiner, four specific regions longer than 50 nucleotides in the SARS-CoV-2 genome were identified. Primers were designed to target the longest and previously untargeted nsp2 region and optimized as a probe-free real-time reverse transcription-polymerase chain reaction (RT-PCR) assay. The new COVID-19-nsp2 assay had a limit of detection (LOD) of 1.8 TCID50/mL and did not amplify other human-pathogenic coronaviruses and respiratory viruses. Assay reproducibility in terms of cycle threshold (Cp) values was satisfactory, with the total imprecision (% CV) values well below 5%. Evaluation of the new assay using 59 clinical specimens from 14 confirmed cases showed 100% concordance with our previously developed COVID-19-RdRp/Hel reference assay. A rapid, sensitive, SARS-CoV-2-specific real-time RT-PCR assay, COVID-19-nsp2, was developed."],"journal":"Int J Mol Sci","authors":["Yip, Cyril Chik-Yan","Ho, Chi-Chun","Chan, Jasper Fuk-Woo","To, Kelvin Kai-Wang","Chan, Helen Shuk-Ying","Wong, Sally Cheuk-Ying","Leung, Kit-Hang","Fung, Agnes Yim-Fong","Ng, Anthony Chin-Ki","Zou, Zijiao","Tam, Anthony Raymond","Chung, Tom Wai-Hin","Chan, Kwok-Hung","Hung, Ivan Fan-Ngai","Cheng, Vincent Chi-Chung","Tsang, Owen Tak-Yin","Tsui, Stephen Kwok Wing","Yuen, Kwok-Yung"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32276333","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.3390/ijms21072574","keywords":["covid-19","covid-19-nsp2 assay","golaymetaminer","sars-cov-2","clinical evaluation","genome subtraction","nsp2","real-time rt-pcr","sensitivity","specificity"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491602337792,"score":359.71127},{"pmid":32335089,"pmcid":"PMC7179514","title":"Highly sensitive detection of SARS-CoV-2 RNA by multiplex rRT-PCR for molecular diagnosis of COVID-19 by clinical laboratories.","text":["Highly sensitive detection of SARS-CoV-2 RNA by multiplex rRT-PCR for molecular diagnosis of COVID-19 by clinical laboratories.","BACKGROUND: The detection of SARS-CoV-2 RNA by real-time reverse transcription-polymerase chain reaction (rRT-PCR) is used to confirm the clinical diagnosis of COVID-19 by molecular diagnostic laboratories. We developed a multiplex rRT-PCR methodology for the detection of SARS-CoV-2 RNA. METHODS: Three genes were used for multiplex rRT-PCR: the Sarbecovirus specific E gene, the SARS-CoV-2 specific N gene, and the human ABL1 gene as an internal control. RESULTS: Good correlation of Cq values was observed between the simplex and multiplex rRT-PCR methodologies. Low copies (<25 copies/reaction) of SARS-CoV-2 RNA were detected by the novel multiplex rRT-PCR method. CONCLUSION: The proposed multiplex rRT-PCR methodology will enable highly sensitive detection of SARS-CoV-2 RNA, reducing reagent use and cost, and time required by clinical laboratory technicians.","Clin Chim Acta","Ishige, Takayuki","Murata, Shota","Taniguchi, Toshibumi","Miyabe, Akiko","Kitamura, Kouichi","Kawasaki, Kenji","Nishimura, Motoi","Igari, Hidetoshi","Matsushita, Kazuyuki","32335089"],"abstract":["BACKGROUND: The detection of SARS-CoV-2 RNA by real-time reverse transcription-polymerase chain reaction (rRT-PCR) is used to confirm the clinical diagnosis of COVID-19 by molecular diagnostic laboratories. We developed a multiplex rRT-PCR methodology for the detection of SARS-CoV-2 RNA. METHODS: Three genes were used for multiplex rRT-PCR: the Sarbecovirus specific E gene, the SARS-CoV-2 specific N gene, and the human ABL1 gene as an internal control. RESULTS: Good correlation of Cq values was observed between the simplex and multiplex rRT-PCR methodologies. Low copies (<25 copies/reaction) of SARS-CoV-2 RNA were detected by the novel multiplex rRT-PCR method. CONCLUSION: The proposed multiplex rRT-PCR methodology will enable highly sensitive detection of SARS-CoV-2 RNA, reducing reagent use and cost, and time required by clinical laboratory technicians."],"journal":"Clin Chim Acta","authors":["Ishige, Takayuki","Murata, Shota","Taniguchi, Toshibumi","Miyabe, Akiko","Kitamura, Kouichi","Kawasaki, Kenji","Nishimura, Motoi","Igari, Hidetoshi","Matsushita, Kazuyuki"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32335089","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.cca.2020.04.023","keywords":["covid-19","high-sensitive","molecular diagnosis","multiplex","sars-cov-2","rrt-pcr"],"locations":["Sarbecovirus"],"topics":["Diagnosis"],"weight":1,"_version_":1666138494101094400,"score":355.68924}]}